Company AB Science

AB

FR0010557264

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 19:55:00 17/07/2026 +04			5-day change	1st Jan Change
0.6120 ^EUR	-0.97%		-16.51%	-60.16%

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules

Business description: AB Science

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Number of employees: 31

Sales by Activity: AB Science

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Pharmaceuticals	1.61M	958K	970K	1.07M	1.17M

See all business segments

Geographical breakdown of sales: AB Science

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Europe	-	-	-	-	955K
outside Europe	-	-	-	-	219K

See all geographic segments

Executive Committee: AB Science

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018
Alexis Bernard PRN	Corporate Officer/Principal	-	-

See AB SCIENCE governance

Composition of the Board of Directors: AB Science

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021
Catherine Johnston-Roussillon BRD	Director/Board Member	68	27/06/2021
Guillemette Latscha BRD	Director/Board Member	-	27/06/2021
Stéphane Ledermann CHM	Chairman	-	07/07/2026

Composition of the Board of Directors

Shareholders: AB Science

Name	Stocks	%	Valuation
UBS Wealth Management SGIIC SA 0.004443 %	3,100	0.004443 %	3 137 €

Name	Stocks	%	Valuation
Friedland Gestion SAS 5.198 %	85,471	5.198 %	32 638 €

Name	Stocks	%	Valuation
Friedland Gestion SAS 4.167 %	64,103	4.167 %	20 081 €

List of AB SCIENCE shareholders

Company details: AB Science

AB Science SA

3, avenue George V

75008, Paris

+33 1 47 20 00 14

http://www.ab-science.com

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-0.97%	-16.51%	-50.72%	-84.58%	56.03M
MERCK & CO., INC.	-0.10%	+3.21%	+59.45%	+20.34%	315B
MERCK KGAA	-1.20%	-2.43%	+23.24%	-8.31%	67.81B
HALOZYME THERAPEUTICS, INC.	+0.35%	+2.11%	+37.84%	+86.59%	9.23B
KYOWA KIRIN CO., LTD.	+0.34%	+0.51%	+5.21%	-0.69%	8.56B
SK BIOPHARMACEUTICALS CO., LTD.	+1.53%	-3.64%	-22.91%	+5.31%	4.18B
BETTA PHARMACEUTICALS CO., LTD.	-11.03%	-12.07%	-8.02%	+14.00%	3.59B
YUHAN CORPORATION	+1.87%	+3.36%	-46.36%	+28.62%	3.55B
SUPERNUS PHARMACEUTICALS, INC.	-0.35%	-0.87%	+48.55%	+60.56%	2.79B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-7.41%	-2.37%	+3.91%	-23.64%	2.09B
Average	-1.70%	-3.20%	+5.02%	+9.82%	41.68B
Weighted average by Cap.	-0.36%	+1.02%	+49.29%	+16.61%